Literature DB >> 16819436

Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients.

J Keates-Baleeiro1, P Moore, T Koyama, B Manes, C Calder, H Frangoul.   

Abstract

Idiopathic pneumonia syndrome (IPS) is a rare complication following stem cell transplant (SCT) and its incidence among pediatric SCT recipients is not known. To assess the incidence of IPS, we retrospectively reviewed the incidence of IPS at our center. IPS is defined as the presence of multilobar infiltrates by chest radiograph or computed tomography scan, need for supplemental oxygenation with declining pulse oximetry and no identifiable pulmonary infection. Between July 1999 and August 2005, 11 of 93 children who received a fully ablative allogeneic SCT (11.8%) developed IPS. All 11 patients had normal pulmonary evaluation before transplant. IPS developed at a median of 17 days (range 8-42 days) after transplant. Recipients of unrelated donor transplant had increased risk of developing IPS. There was a significant association between acute or hyperacute graft-versus-host disease (GVHD) and IPS (P=0.035). All patients had significant hypoxia and five patients required assisted ventilation. IPS was the cause of death in two patients. Although there was complete resolution of respiratory symptoms in the other nine patients, overall transplant-related mortality was significantly higher among patients with IPS (64 vs 17%, P=0.002). IPS is a relatively common complication in pediatric SCT recipients and acute GVHD is an important associated factor.

Entities:  

Mesh:

Year:  2006        PMID: 16819436     DOI: 10.1038/sj.bmt.1705436

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  20 in total

Review 1.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

Review 2.  Recent Advancements in Intestinal Microbiota Analyses: A Review for Non-Microbiologists.

Authors:  Xiao-Wei Feng; Wen-Ping Ding; Ling-Yun Xiong; Liang Guo; Jia-Ming Sun; Peng Xiao
Journal:  Curr Med Sci       Date:  2018-12-07

3.  Proteome Profiling in Lung Injury after Hematopoietic Stem Cell Transplantation.

Authors:  Maneesh Bhargava; Kevin J Viken; Sanjoy Dey; Michael S Steinbach; Baolin Wu; Pratik D Jagtap; LeeAnn Higgins; Angela Panoskaltsis-Mortari; Daniel J Weisdorf; Vipin Kumar; Mukta Arora; Peter B Bitterman; David H Ingbar; Chris H Wendt
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-05       Impact factor: 5.742

4.  Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation.

Authors:  Sachiko Seo; Jeffrey Yu; Isaac C Jenkins; Wendy M Leisenring; Terry Steven-Ayers; Jane M Kuypers; Meei-Li Huang; Keith R Jerome; Michael Boeckh; Sophie Paczesny
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-06       Impact factor: 5.742

5.  Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children.

Authors:  H Sano; R Kobayashi; A Iguchi; D Suzuki; K Kishimoto; K Yasuda; K Kobayashi
Journal:  Bone Marrow Transplant       Date:  2013-08-19       Impact factor: 5.483

6.  TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521).

Authors:  Gregory A Yanik; Stephan A Grupp; Michael A Pulsipher; John E Levine; Kirk R Schultz; Donna A Wall; Bryan Langholz; Christopher C Dvorak; Keith Alangaden; Rakesh K Goyal; Eric S White; Jennifer M Collura; Micah A Skeens; Saada Eid; Elizabeth M Pierce; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-28       Impact factor: 5.742

7.  Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.

Authors:  Sulaiman Al-Hashmi; Zuzana Hassan; Behnam Sadeghi; Björn Rozell; Moustapha Hassan
Journal:  Int J Clin Exp Pathol       Date:  2011-07-31

8.  Emergent Complications in the Pediatric Hematopoietic Stem Cell Transplant Patient.

Authors:  Ashley Munchel; Allen Chen; Heather Symons
Journal:  Clin Pediatr Emerg Med       Date:  2011-09

9.  Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies.

Authors:  Sachiko Seo; Christian Renaud; Jane M Kuypers; Charles Y Chiu; Meei-Li Huang; Erik Samayoa; Hu Xie; Guixia Yu; Cynthia E Fisher; Ted A Gooley; Steven Miller; Robert C Hackman; David Myerson; Ruth H Sedlak; Yae-Jean Kim; Takahiro Fukuda; David N Fredricks; David K Madtes; Keith R Jerome; Michael Boeckh
Journal:  Blood       Date:  2015-04-27       Impact factor: 22.113

10.  Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary.

Authors:  Robert F Tamburro; Kenneth R Cooke; Stella M Davies; Samuel Goldfarb; James S Hagood; Ashok Srinivasan; Marie E Steiner; Dennis Stokes; Nancy DiFronzo; Nahed El-Kassar; Nonniekaye Shelburne; Aruna Natarajan
Journal:  Ann Am Thorac Soc       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.